| 摘要 |
Disclosed is the use of a replication-defective recombinant adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite, and an adjuvated proteinaceous antigen selected from a CS protein or an immunogenic fragment thereof comprising a C-terminal portion of the CS protein, four or more tandem repeats of the immunodominant region, and the surface antigen from hepatitis B virus, wherein said proteinaceous antigen is adjuvated with an adjuvant comprising QS21 and 3D-MPL in the manufacture of a medicament for the treatment or prevention of malaria, wherein said recombinant adenovirus is a simian, a canine, a bovine adenovirus or a human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 or 50.
|
| 申请人 |
GLAXOSMITHKLINE BIOLOGICALS, S.A.;CRUCELL HOLLAND B.V.;THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH |
发明人 |
HEPPNER, DONALD G;PAU, MARIA GRAZIA;GOUDSMIT, JAAP;DUBOIS, PATRICE M;STEWART V |
